Skip to content

Maryland

Psychedelic trials in Maryland

90 registered trials has a study site in Maryland, and 23 are recruiting now.

90
Trials with a site here
23
Recruiting
40
Facilities

Open now

Recruiting in this state

TrialStatusPhaseSubstanceSites
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL LimitedRecruitingPhase 3psilocybin68
Neurobiology of SuicideNCT02543983 · National Institute of Mental Health (NIMH)RecruitingPhase 2ketamine1
Effects of Psilocybin on Electrophysiology and the Dynamic Content of ThoughtNCT05301608 · Johns Hopkins UniversityRecruitingPhase 1 / Phase 2psilocybin1
Psilocybin Efficacy With or Without Pimavanserin PretreatmentNCT07610135 · Johns Hopkins UniversityRecruitingPhase 1 / Phase 2psilocybin1
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use DisorderNCT06067737 · Johns Hopkins UniversityRecruitingPhase 2psilocybin1
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant DepressionNCT06511908 · National Institute of Mental Health (NIMH)RecruitingPhase 2ketamine1
Psilocybin-Assisted Therapy for Sexual Assault-Related PTSDNCT06902974 · Sunstone MedicalRecruitingPhase 2psilocybin1
MDMA Therapy in Veterans With PTSDNCT07569159 · Sunstone MedicalRecruitingPhase 2mdma1
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderNCT05452772 · Johns Hopkins UniversityRecruitingPhase 2psilocybin3
MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant OtherNCT05584826 · Sunstone MedicalRecruitingPhase 2mdma1
Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSDNCT06608277 · Northwestern UniversityRecruitingPhase 2ketamine3
Ketamine for Opioid Use DisorderNCT06943859 · University of Maryland, BaltimoreRecruitingPhase 2ketamine1
Pragmatic Trial of Psilocybin Therapy in Palliative CareNCT05403086 · Charles S. Grob, M.D.RecruitingPhase 2psilocybin, ketamine5
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderNCT03065335 · National Institute of Mental Health (NIMH)RecruitingPhase 1ketamine1
Psilocybin in Chronic Low Back Pain and DepressionNCT06355414 · Johns Hopkins UniversityRecruitingPhase 1psilocybin1
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major DepressionNCT03973268 · National Institute of Mental Health (NIMH)RecruitingPhase 1ketamine1
Psilocybin-assisted Treatment for Cannabis Use DisorderNCT06660381 · Johns Hopkins UniversityRecruitingPhase 1psilocybin1
Investigation of Psychedelic Effects in Psychoactive SubstancesNCT06772753 · Johns Hopkins UniversityRecruitingPhase 1psilocybin, mdma, dmt1
Psychedelic Healing: Adjunct Therapy Harnessing Opened MalleabilityNCT07053917 · Johns Hopkins UniversityRecruitingPhase 1psilocybin1
Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)NCT06989957 · Johns Hopkins UniversityRecruitingPhase 1psilocybin, mdma1
Psilocybin Administration With 5-HT1a BlockadeNCT07565493 · Johns Hopkins UniversityRecruitingEarly Phase 1psilocybin1
Effects of Psilocybin in Patients With Amyotrophic Lateral SclerosisNCT06656702 · Johns Hopkins UniversityRecruitingEarly Phase 1psilocybin1
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's DiseaseNCT04123314 · Johns Hopkins UniversityRecruitingEarly Phase 1psilocybin1

Facilities

Where the research happens in Maryland

FacilityCityTrials
Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore12
Sheppard Pratt Health SystemBaltimore10
National Institutes of Health Clinical CenterBethesda5
Sunstone Medical, PCRockville5
Sunstone TherapiesRockville5
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical CenterBaltimore5
Johns Hopkins University School of MedicineBaltimore4
CBH HealthGaithersburg4
Johns Hopkins UniversityBaltimore3
Behavioral Pharmacology Research UnitBaltimore3
Walter Reed National Military Medical CenterBethesda2
Sheppard PrattBaltimore2
Johns Hopkins MedicineBaltimore1
University of Maryland Addiction Programs and Affiliated ClinicsBaltimore1
Johns HopkinsBaltimore1
Center for Psychedelics and Consciousness ResearchBaltimore1
Johns Hopkins HospitalBaltimore1
Johns Hopkins Burn CenterBaltimore1
CBH Health, LLCGaithersburg1
Pharmasite Research, IncPikesville1
Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness ResearchBaltimore1
Sunstone Medical PCRockville1
John Hopkins HospitalBaltimore1
National Institute of Aging, Clinical Research UnitBaltimore1
Clinical Site 108Gaithersburg1
Walter Reed National Military Medical Center (WRNMC)Bethesda1
Clinical Site 131Baltimore1
Clinical Site 136Rockville1
Seelos Investigational SiteGaithersburg1
Maryland Oncology Hematology PARockville1
Novartis Investigative SiteRockville1
National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda1
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview CampusBaltimore1
5510 Nathan Shock DriveBaltimore1
Johns Hopkins School of MedicineBaltimore1
Center for Psychedelics and Consciousness Research in the Behavioral Biology Research CenterBaltimore1
Behavioral Biology Research Center, Johns Hopkins BayviewBaltimore1
University of Maryland BaltimoreBaltimore1
National Institute on Drug Abuse, Biomedical Research Center (BRC)Baltimore1
Clinical Research SiteGaithersburg1

Stay told

When a trial opens in Maryland

Research alerts

Get a notification when a trial for trials in Maryland starts recruiting

This registry is rebuilt every day. If no trial is recruiting for you today, that can change within weeks.

This form sends your email address and the topic of this page to Brevo, our email provider, which stores them on servers in the European Union. We never sell that address, never share it with anyone, and never use it for advertising. One email deletes it. What is held, and where.

All trials

Every trial with a Maryland site

TrialStatusPhaseSubstanceSites
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL LimitedRecruitingPhase 3psilocybin68
Neurobiology of SuicideNCT02543983 · National Institute of Mental Health (NIMH)RecruitingPhase 2ketamine1
Effects of Psilocybin on Electrophysiology and the Dynamic Content of ThoughtNCT05301608 · Johns Hopkins UniversityRecruitingPhase 1 / Phase 2psilocybin1
Psilocybin Efficacy With or Without Pimavanserin PretreatmentNCT07610135 · Johns Hopkins UniversityRecruitingPhase 1 / Phase 2psilocybin1
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use DisorderNCT06067737 · Johns Hopkins UniversityRecruitingPhase 2psilocybin1
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant DepressionNCT06511908 · National Institute of Mental Health (NIMH)RecruitingPhase 2ketamine1
Psilocybin-Assisted Therapy for Sexual Assault-Related PTSDNCT06902974 · Sunstone MedicalRecruitingPhase 2psilocybin1
MDMA Therapy in Veterans With PTSDNCT07569159 · Sunstone MedicalRecruitingPhase 2mdma1
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderNCT05452772 · Johns Hopkins UniversityRecruitingPhase 2psilocybin3
MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant OtherNCT05584826 · Sunstone MedicalRecruitingPhase 2mdma1
Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSDNCT06608277 · Northwestern UniversityRecruitingPhase 2ketamine3
Ketamine for Opioid Use DisorderNCT06943859 · University of Maryland, BaltimoreRecruitingPhase 2ketamine1
Pragmatic Trial of Psilocybin Therapy in Palliative CareNCT05403086 · Charles S. Grob, M.D.RecruitingPhase 2psilocybin, ketamine5
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderNCT03065335 · National Institute of Mental Health (NIMH)RecruitingPhase 1ketamine1
Psilocybin in Chronic Low Back Pain and DepressionNCT06355414 · Johns Hopkins UniversityRecruitingPhase 1psilocybin1
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major DepressionNCT03973268 · National Institute of Mental Health (NIMH)RecruitingPhase 1ketamine1
Psilocybin-assisted Treatment for Cannabis Use DisorderNCT06660381 · Johns Hopkins UniversityRecruitingPhase 1psilocybin1
Investigation of Psychedelic Effects in Psychoactive SubstancesNCT06772753 · Johns Hopkins UniversityRecruitingPhase 1psilocybin, mdma, dmt1
Psychedelic Healing: Adjunct Therapy Harnessing Opened MalleabilityNCT07053917 · Johns Hopkins UniversityRecruitingPhase 1psilocybin1
Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)NCT06989957 · Johns Hopkins UniversityRecruitingPhase 1psilocybin, mdma1
Psilocybin Administration With 5-HT1a BlockadeNCT07565493 · Johns Hopkins UniversityRecruitingEarly Phase 1psilocybin1
Effects of Psilocybin in Patients With Amyotrophic Lateral SclerosisNCT06656702 · Johns Hopkins UniversityRecruitingEarly Phase 1psilocybin1
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's DiseaseNCT04123314 · Johns Hopkins UniversityRecruitingEarly Phase 1psilocybin1
Comparative Effectiveness of ECT vs. KETAMINE Over the LifespanNCT06034821 · Brigham and Women's HospitalEnrolling by invitationPhase 4ketamine10
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionNCT04599855 · Janssen Research & Development, LLCCompletedPhase 4ketamine54
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.NCT03156504 · Mayo ClinicCompletedPhase 4ketamine4
RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn PainNCT03305055 · Johns Hopkins UniversityTerminatedPhase 4ketamine1
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · Cybin IRL LimitedActive, not recruitingPhase 3psilocybin45
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDNCT05624268 · COMPASS PathwaysCompletedPhase 3psilocybin40
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)NCT06809595 · Definium Therapeutics US, Inc.Active, not recruitingPhase 3lsd36
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)NCT06941844 · Definium Therapeutics US, Inc.Active, not recruitingPhase 3lsd22
Psilocybin for Major Depressive Disorder (MDD)NCT06308653 · Usona InstituteActive, not recruitingPhase 3psilocybin29
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02417064 · Janssen Research & Development, LLCCompletedPhase 3ketamine90
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02418585 · Janssen Research & Development, LLCCompletedPhase 3ketamine48
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant DepressionNCT02422186 · Janssen Research & Development, LLCCompletedPhase 3ketamine69
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionNCT02493868 · Janssen Research & Development, LLCCompletedPhase 3ketamine155
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant DepressionNCT02497287 · Janssen Research & Development, LLCCompletedPhase 3ketamine109
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionNCT02782104 · Janssen Research & Development, LLCCompletedPhase 3ketamine173
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03039192 · Janssen Research & Development, LLCCompletedPhase 3ketamine56
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03097133 · Janssen Research & Development, LLCCompletedPhase 3ketamine61
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT03434041 · Janssen Research & Development, LLCCompletedPhase 3ketamine30
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)NCT03113968 · Bo HuCompletedPhase 2 / Phase 3ketamine5
Neuroplasticity Enhancement From Cognitive Training Reinforced by PsilocybinNCT07721467 · National Institute on Aging (NIA)Not yet recruitingPhase 2psilocybin1
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive DisorderNCT06340958 · Clexio Biosciences Ltd.CompletedPhase 2ketamine23
Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002NCT06816433 · Global Coalition for Adaptive ResearchSuspendedPhase 2ketamine9
Two Doses of Psilocybin for the Treatment of MDD in Adults With CancerNCT05947383 · Sunstone MedicalActive, not recruitingPhase 2psilocybin1
A Study of Psilocybin for Major Depressive Disorder (MDD)NCT03866174 · Usona InstituteCompletedPhase 2psilocybin11
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use DisorderNCT04620759 · Johns Hopkins UniversityActive, not recruitingPhase 2psilocybin1
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety SymptomsNCT05407064 · Definium Therapeutics US, Inc.CompletedPhase 2lsd22
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use DisorderNCT06005662 · Johns Hopkins UniversityWithdrawnPhase 2psilocybin1
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal IdeationNCT05220410 · Sheppard Pratt Health SystemCompletedPhase 2psilocybin1
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO StudyNCT04103892 · Clexio Biosciences Ltd.CompletedPhase 2ketamine46
Trifecta Research StudyNCT06810765 · Johns Hopkins UniversityWithdrawnPhase 2dmt, ibogaine1
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderNCT05733546 · COMPASS PathwaysActive, not recruitingPhase 2psilocybin5
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderNCT05312151 · COMPASS PathwaysCompletedPhase 2psilocybin3
A Study of Ketamine in Patients With Treatment-resistant DepressionNCT01627782 · Janssen Research & Development, LLCCompletedPhase 2ketamine13
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant DepressionNCT01998958 · Janssen Research & Development, LLCCompletedPhase 2ketamine25
A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for SuicideNCT02133001 · Janssen Research & Development, LLCCompletedPhase 2ketamine14
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideNCT03185819 · Janssen Research & Development, LLCCompletedPhase 2ketamine51
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept StudyNCT05481736 · COMPASS PathwaysCompletedPhase 2psilocybin5
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)NCT04433858 · Sheppard Pratt Health SystemActive, not recruitingPhase 2psilocybin2
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of SuicideNCT04669665 · Seelos Therapeutics, Inc.CompletedPhase 2ketamine21
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionNCT03775200 · COMPASS PathwaysCompletedPhase 2psilocybin25
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.NCT04433845 · Sheppard Pratt Health SystemUnknown statusPhase 2psilocybin1
Effects of Psilocybin in Major Depressive DisorderNCT03181529 · Johns Hopkins UniversityCompletedPhase 2psilocybin1
The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive DisorderNCT04593563 · Maryland Oncology Hematology, PAUnknown statusPhase 2psilocybin1
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant DepressionNCT03756129 · Novartis PharmaceuticalsCompletedPhase 2ketamine12
Persisting Effects of PsilocybinNCT02971605 · Johns Hopkins UniversityCompletedPhase 1 / Phase 2psilocybin1
Rapid Antidepressant Effects of Ketamine in Major DepressionNCT00088699 · National Institute of Mental Health (NIMH)CompletedPhase 1 / Phase 2ketamine1
Psychopharmacology of Psilocybin in Cancer PatientsNCT00465595 · Johns Hopkins UniversityCompletedPhase 2psilocybin1
Safety for Home Administration of Microdose Psilocybin UseNCT06450210 · Johns Hopkins UniversityCompletedPhase 1psilocybin1
Psilocybin Brain Stimulation and Imaging Pilot StudyNCT06835699 · Johns Hopkins UniversityCompletedPhase 1psilocybin1
Shortened LSD Intervention for Major Depressive DisorderNCT07503002 · Johns Hopkins UniversityNot yet recruitingPhase 1lsd1
A Study of Psilocybin for PTSDNCT06407635 · Johns Hopkins UniversityActive, not recruitingPhase 1psilocybin1
PRoMiSS: Psilocybin and the Role of Music in Set and SettingNCT07180108 · Johns Hopkins UniversityEnrolling by invitationPhase 1psilocybin1
Effects of Psilocybin in Post-Treatment Lyme DiseaseNCT05305105 · Johns Hopkins UniversityCompletedPhase 1psilocybin1
A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant DepressionNCT05268497 · Janssen Research & Development, LLCWithdrawnPhase 1ketamine5
Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in ReligionNCT02243813 · Johns Hopkins UniversityCompletedPhase 1psilocybin1
Ketamine for OUD and Comorbid Depression (OUDCD)NCT05051449 · University of Maryland, BaltimoreTerminatedPhase 1ketamine1
[11C]-(R)-Rolipram to Measure cAMP Signaling Before and After KetamineNCT05522673 · National Institute of Mental Health (NIMH)TerminatedPhase 1ketamine1
Effects of Psilocybin in Anorexia NervosaNCT04052568 · Johns Hopkins UniversityCompletedPhase 1psilocybin1
Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term MeditatorsNCT02145091 · Johns Hopkins UniversityCompletedPhase 1psilocybin1
Neurobiology and Pharmacokinets of Acute MDMA AdministrationNCT01148342 · National Institute on Drug Abuse (NIDA)CompletedPhase 1mdma1
Ketamine for Major Depressive DisorderNCT03721900 · Shenox Pharmaceuticals, LLCUnknown statusPhase 1ketamine3
Psilocybin and Spiritual PracticeNCT00802282 · Johns Hopkins UniversityCompletedPhase 1psilocybin1
Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term MeditatorsNCT01988311 · Johns Hopkins UniversityCompletedPhase 1psilocybin1
Effects of Psilocybin in Obsessive Compulsive DisorderNCT05546658 · Johns Hopkins UniversityActive, not recruitingEarly Phase 1psilocybin1
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot StudyNCT01943994 · Johns Hopkins UniversityCompletedNot applicablepsilocybin2
A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSDNCT04438512 · Resilient PharmaceuticalsNo longer availableN/Amdma2
Retrospective Evaluation of Ketamine Effectiveness for the Treatment of Acute Battlefield Related PainNCT04057989 · Defense and Veterans Center for Integrative Pain ManagementCompletedN/Aketamine1

Site locations from ClinicalTrials.gov API v2, data build 2026-08-25.

Elsewhere

Other states